Cattle spleen peptide lysine formula milk powder for children growth and preparation method of cattle spleen peptide lysine formula milk powder

Abstract

The invention discloses cattle spleen peptide lysine children growth formula milk powder and a preparation method thereof, and belongs to the technical field of milk powder. Comprises, by mass, 550-600 parts of whole milk powder, 150-200 parts of dried skim milk, 160-190 parts of isomaltooligosacharide (type 50) powder, 25-35 parts of polydextrose, 25-30 parts of edible plant blend oil, 3-5 parts of milk mineral salt and 12-15 parts of a compound modified milk powder three-nutrition enhancer for children. The microcapsule technology is adopted, so that the bovine spleen peptide lysine is dissolved quickly, stably and lastingly; the DHA, the ARA, the breast milk oligosaccharide and the coated probiotics are cooperated to promote the development of brain and eyes and the balance of intestinal tracts; and the milk calcium and the collagen peptide strengthen bones. Activity is protected by a low-temperature process, and preservation is prolonged by nitrogen packaging. Clinical verifications prove that the traditional Chinese medicine composition promotes growth, improves sleep and comprehensively supports growth of children.

Description

Technical Field

[0001] This invention relates to the field of infant formula technology, specifically to a bovine spleen peptide lysine-based infant formula and its preparation method. Background Technology

[0002] In the field of infant formula, bovine spleen peptide lysine has attracted much attention due to its calcium absorption-promoting and immune-regulating functions. However, there are significant drawbacks in incorporating it into the formula system using current technologies: Defects in solubility and reconstitution stability: Bovine spleen peptide lysine powder is not modified (particle size is usually >100μm). Direct addition will lead to: high sedimentation rate (>15%, GB / T 5413.28-2017), formation of insoluble clumps, excessively long dissolution time (>120 seconds), poor consumer experience (market survey complaint rate ≥23%), uneven distribution of active ingredients (mixing coefficient of variation CV>10%), and reduced bioavailability.

[0003] pH conflict caused system instability. The natural pH of bovine spleen peptide lysine (6.0±0.2) differed significantly from the milk base pH (6.6-6.8), leading to: protein denaturation and aggregation: the acidic environment of bovine spleen peptide lysine caused whey protein isoelectric point precipitation, resulting in visible stratification (stratification rate >30%) after 3 months of storage; insufficient buffering capacity: traditional regulators such as calcium carbonate could not accurately control the microenvironment, with pH fluctuations >0.5 (GB 5009.237-2016), accelerating the degradation of functional components; and probiotic inactivation: pH shift reduced the survival rate of Bifidobacteria to ≤80% (compared to the initial value).

[0004] Poor process adaptability: Existing dry mixing processes cannot solve the problems caused by the characteristics of bovine spleen peptide lysine: High temperature destroys activity: One-step mixing requires >30 minutes, mechanical friction raises the temperature to 25-30℃, resulting in thermal denaturation of bovine spleen peptide lysine (activity loss ≥20%), DHA oxidation rate >8% (gas chromatography detection), failure of moisture control: Bovine spleen peptide lysine is highly hygroscopic (saturated moisture absorption rate 12.5%), and clumps after mixing with base powder with >4.5% moisture (hardness >50N, texture analyzer test), no dynamic pH control: Acid-base imbalance during mixing cannot be corrected in real time, resulting in poor pH uniformity of the finished product solution (range >0.8). Summary of the Invention

[0005] The purpose of this invention is to provide a bovine spleen peptide lysine-based infant formula milk powder and its preparation method. This formula milk powder, through microencapsulation technology, significantly improves the solubility and stability of bovine spleen peptide lysine, ensuring clumping-free mixing and long-lasting nutrient retention. The formula incorporates human milk oligosaccharides, DHA, ARA, and bifidobacteria to protect the brain and gut, and prevent allergies and diarrhea; milk calcium and collagen peptides synergistically promote bone growth. Low-temperature warm air drying, segmented temperature-controlled mixing, and nitrogen-filled packaging lock in activity and freshness. Real-world testing showed that after three months of continuous consumption, children grew faster, slept more soundly, and had better gut health, comprehensively supporting healthy growth.

[0006] To achieve the above effects, the present invention provides the following technical solution: a bovine spleen peptide lysine infant formula milk powder, comprising the following mass fractions: Wet process portion: 550-600 parts whole milk powder, 150-200 parts skim milk powder, 160-190 parts isomaltooligosaccharide (type 50) powder, 25-35 parts polydextrose, 25-30 parts edible vegetable blended oil, 3-5 parts milk mineral salts, and 12-15 parts compounded infant formula fortifier. Dry processing portion: 10-15 parts emulsified bovine spleen peptide lysine powder, 7-8 parts 2'-fucosylated lactose, 5-7 parts docosahexaenoic acid, 3-5 parts arachidonic acid, 1-3 parts collagen peptide powder, 1.0-1.5 parts probiotic complex, and 0.5-1 part pH adjuster; The emulsified bovine spleen peptide lysine powder contains 30% to 40% bovine spleen peptide lysine. The emulsified bovine spleen peptide lysine powder is prepared by encapsulating bovine spleen peptide lysine powder through a phospholipid-sucrose ester composite emulsion, with a particle size ≤50μm and pH 6.5~6.7; The probiotic complex contains ≥1×10⁻⁶ live bacteria of Bifidobacterium lactis subsp. Lactobacillus Bb-12 and HN019. 9 CFU / g; The natural extracts include 1 part chicken gizzard powder extract, 1 part hawthorn powder extract, 0.5 parts Poria cocos powder extract, 0.5 parts yam powder extract, 0.5 parts jujube powder extract and 0.5 parts coix seed powder extract; The pH adjuster is prepared by mixing sodium bicarbonate and trisodium citrate in a ratio of 2:1.

[0007] Furthermore, the preparation method of the emulsified bovine spleen peptide lysine powder includes: Bovine spleen peptide lysine powder, phospholipids, and sucrose esters are dissolved in pure water at 40-45℃ in a mass ratio of 10:(0.8-1.2):(0.3-0.5). The homogenization pressure is 35-40MPa, and the spray drying inlet air temperature is ≤130℃.

[0008] Furthermore, the pH adjuster is encapsulated in the maltodextrin carrier in microcapsule form before dry mixing, with an encapsulation rate of ≥95%.

[0009] Furthermore, the probiotic complex contains Bifidobacterium lactis subsp. Bb-12 and Bifidobacterium lactis subsp. HN019 in a 1:1 ratio, and is pre-coated with L-ascorbic acid sodium.

[0010] Furthermore, the mass ratio of the emulsified bovine spleen peptide lysine powder to polydextrose is 1:(2-3).

[0011] A method for preparing bovine spleen peptide lysine-based infant formula milk powder, applicable to any one of the above-mentioned bovine spleen peptide lysine-based infant formula milk powders, includes the following steps: S1. Preparation of wet-process base powder: Mix the wet-process components with water evenly, pasteurize and then spray dry, controlling the moisture content of the base powder to ≤4.5% and the pH to 6.6~6.8; S2, Bovine spleen peptide lysine pretreatment: Emulsified bovine spleen peptide lysine powder is premixed with pH adjuster and bone collagen peptide powder to form a homogeneous powder. S3, gradient mixing; Gradient mixing specifically includes the following steps: S301. Mix the powder obtained in step 2 with docosahexaenoic acid and arachidonic acid at low speed under nitrogen protection, 10-15 rpm, for 5 min. S302, add probiotic complex, 2'-fucosylated lactose and natural extract and mix at 20-25℃ for 8 minutes; S303. Transfer the wet-process base powder into a two-dimensional shear mixer and mix it with the aforementioned mixture at 12-15°C in an inert gas environment for 15 minutes. S304, sieved, nitrogen-filled packaging, oxygen residue ≤0.5%.

[0012] Furthermore, in step two, 20% to 30% of the total amount of polydextrose is added as a dispersion carrier during the bovine spleen peptide lysine pretreatment process, and the mixing temperature is ≤30℃.

[0013] Furthermore, the S303 employs segmented temperature control mixing, with the cavity temperature at 12-15°C for the first 5 minutes and then dropping to 8-10°C for the next 10 minutes.

[0014] Furthermore, the gradient mixing process is monitored online, and pH adjustment microcapsules are automatically sprayed when the system pH deviates from 6.6 to 6.7.

[0015] Furthermore, the final milk powder reconstitution sedimentation rate is ≤3.5%, the bovine spleen peptide lysine solubility rate is ≥98%, and the pH stability change value after 6 months of storage at 25℃ is ≤0.2.

[0016] This invention provides a bovine spleen peptide lysine-based infant formula milk powder and its preparation method, which has the following beneficial effects: (1) In this invention, by encapsulating bovine spleen peptide lysine with phospholipid-sucrose ester through emulsification, a microcapsule structure with a particle size ≤50μm is formed, which significantly improves the solubility of active peptides during reconstitution to over 98% and reduces the sedimentation rate to below 3.5%, making the milk powder disperse faster and more evenly in water, avoiding clumping and sticking to the walls. After being encapsulated, the bovine spleen peptide lysine is stored at 25℃ for 6 months with a pH change of ≤0.2, and its stability is better than the national standard, ensuring that the nutrients maintain their activity for a long time.

[0017] (2) In this invention, 2'-fucosylated lactose, DHA, and ARA in the formula are mixed in stages under nitrogen protection to avoid oxidative loss and synergistically promote the development of the retina and brain nerves in infants and young children; the probiotic complex is pre-coated with L-ascorbic acid sodium, which increases the survival rate at room temperature by 50%, and works together with isomaltooligosaccharide and polydextrose to quickly colonize the intestines, increase the proportion of beneficial bacteria, and reduce the incidence of eczema and diarrhea. The golden ratio of milk mineral salts and bone collagen peptide powder increases calcium absorption by 30%, increases bone density T value by 0.8, and accelerates longitudinal bone growth.

[0018] (3) In this invention, the wet-process base powder is spray-dried at a low temperature of ≤130℃ to reduce Maillard reaction and lysine loss rate <3%; the segmented temperature-controlled mixing first uses molten lipids at 12-15℃ to encapsulate sensitive components, and then cools to 8-10℃ to solidify microcapsules to ensure the activity of DHA, ARA and probiotics; nitrogen-filled packaging controls oxygen residue ≤0.5%, extending shelf life to 24 months. Clinical trials have shown that after 90 days of continuous consumption, children's average height increased by 1.2 cm more than the control group, and the number of nighttime awakenings decreased by 58%, comprehensively promoting physical, intellectual and intestinal health development. Attached Figure Description

[0019] Figure 1 This is a schematic diagram of the process for preparing a bovine spleen peptide lysine-based infant formula milk powder and its preparation method according to the present invention. Detailed Implementation

[0020] To make the objectives, technical solutions, and advantages of this invention clearer, the invention will be further described in detail below with reference to specific embodiments.

[0021] This invention provides a technical solution: Please see Figure 1 Example 1: A bovine spleen peptide lysine infant formula milk powder, comprising the following mass fractions: Wet process portion: 580 parts whole milk powder, 180 parts skim milk powder, 175 parts isomaltooligosaccharide (type 50) powder, 30 parts polydextrose, 28 parts edible vegetable blended oil, 4 parts milk mineral salts, and 13.5 parts compounded infant formula fortifier. Dry processing section: 12 parts emulsified bovine spleen peptide lysine powder (35% bovine spleen peptide lysine content, 45μm particle size, pH 6.6), 7.5 parts 2'-fucosylated lactose, 6 parts docosahexaenoic acid (DHA), 4 parts arachidonic acid (ARA), 4 parts natural extracts (1 part chicken gizzard powder extract, 1 part hawthorn powder extract, 0.5 part Poria cocos powder extract, 0.5 part yam powder extract, 0.5 part jujube powder extract, 0.5 part coix seed powder extract), 2 parts collagen peptide powder, 1.2 parts probiotic complex (containing ≥1×10⁻⁶ live bacteria of Bb-12 and HN019). 9 CFU / g, 1:1 ratio, pre-coated with L-ascorbic acid sodium), 0.8 parts of pH adjuster (sodium bicarbonate: trisodium citrate = 2:1, microcapsules coated with maltodextrin, coating rate 96%) Key ratio control: Emulsified bovine spleen peptide lysine powder : polydextrose = 1 : 2.5 A method for preparing bovine spleen peptide lysine-based infant formula milk powder: S1. Preparation of wet base powder: Mix the wet components with pure water evenly, pasteurize at 85℃ for 15s, and spray dry (inlet air temperature 180℃, outlet air temperature 85℃) to obtain base powder (moisture content 4.2%, pH 6.7).

[0022] S2. Pretreatment of bovine spleen peptide lysine: Take 12 parts of emulsified bovine spleen peptide lysine powder, 0.8 parts of pH adjuster, 2 parts of collagen peptide powder, and 6 parts of polydextrose (accounting for 20% of the total amount), and premix them into homogeneous powder at 28℃.

[0023] S3. Gradient mixing (nitrogen protection): S301: Mix S2 powder with 6 parts DHA and 4 parts ARA at 10 rpm for 5 min; S302: Add 1.2 parts of probiotic complex, 7.5 parts of 2'-fucosylated lactose, and 4 parts of natural extract, and mix at 22℃ for 8 minutes; S303: The wet-process base powder is transferred to a two-dimensional shear mixer and mixed with the above mixture in stages with controlled temperature. First 5min: 14℃, 15rpm; Last 10 minutes: 9℃, 12 rpm; S304: Passed through an 80-mesh sieve, nitrogen-filled packaging (oxygen residue 0.4%).

[0024] Full control: Online pH monitoring (automatic respraying of pH adjuster microcapsules to maintain pH 6.65±0.05); The temperature of the mixing chamber is adjusted in real time based on feedback.

[0025] Please see Figure 1 Example 2: A bovine spleen peptide lysine infant formula milk powder, comprising the following mass fractions: Formula adjustments: 14 parts of emulsified bovine spleen peptide lysine powder (bovine spleen peptide lysine content 38%, particle size 40μm, pH 6.6) Polydextrose 32 parts → Bovine spleen peptide lysine powder: polydextrose = 1:2.3 pH adjuster microcapsule encapsulation rate: 98% Process optimization of a preparation method for bovine spleen peptide lysine-based infant formula milk powder: S2 pretreatment: Add 9.6 parts of polydextrose (30% of total amount), mix at 25℃; S303 segmented temperature control: 12℃ for the first 5 minutes → 8℃ for the last 10 minutes; The residual oxygen content in the packaging is ≤0.3%.

[0026] Comparative Examples (Non-Patent Methods) Violation of regulations: Eliminate the phospholipid-sucrose ester encapsulation of emulsified bovine spleen peptide lysine powder (add raw material powder directly). Mixing temperature runaway: Step S302 involves mixing at 30°C; The powder was added directly without using pH-adjusting microcapsules.

[0027] result: The settling rate was 8.7% (>3.5%). The solubility of lysine in bovine spleen peptides was 82% (<98%). After 3 months of storage, the pH value changed by +0.5 (>0.2).

[0028] Effect verification: The products of Examples 1-2 and the comparative examples were tested, and the parameters are shown in the table below:

[0029] Percentage of viable bacteria after 6 months of storage (initial viable bacteria count ≥ 1.2 × 10⁻⁶) 9 CFU / g).

[0030] Although embodiments of the invention have been shown and described, it will be understood by those skilled in the art that various changes, modifications, substitutions and alterations can be made to these embodiments without departing from the principles and spirit of the invention, the scope of which is defined by the appended claims and their equivalents.

Claims

1. A bovine spleen peptide lysine-based infant formula milk powder, characterized in that, Includes the following mass fractions: Wet process portion: 550-600 parts whole milk powder, 150-200 parts skim milk powder, 160-190 parts isomaltooligosaccharide (type 50) powder, 25-35 parts polydextrose, 25-30 parts edible vegetable blended oil, 3-5 parts milk mineral salts, and 12-15 parts compounded infant formula fortifier. Dry processing portion: 10-15 parts emulsified bovine spleen peptide lysine powder, 7-8 parts 2'-fucosylated lactose, 5-7 parts docosahexaenoic acid, 3-5 parts arachidonic acid, 4 parts natural extract, 1-3 parts collagen peptide powder, 1.0-1.5 parts probiotic complex, and 0.5-1 part pH adjuster; The emulsified bovine spleen peptide lysine powder contains 30% to 40% bovine spleen peptide lysine. The emulsified bovine spleen peptide lysine powder is prepared by encapsulating bovine spleen peptide lysine powder through a phospholipid-sucrose ester composite emulsion, with a particle size ≤50μm and pH 6.5~6.7; The probiotic complex contains ≥1×10⁻⁶ live bacteria of Bifidobacterium lactis subsp. Lactobacillus Bb-12 and HN019. 9 CFU / g; The natural extracts include 1 part chicken gizzard powder extract, 1 part hawthorn powder extract, 0.5 parts Poria cocos powder extract, 0.5 parts yam powder extract, 0.5 parts jujube powder extract and 0.5 parts coix seed powder extract; The pH adjuster is prepared by mixing sodium bicarbonate and trisodium citrate in a ratio of 2:

1.

2. The milk powder according to claim 1, characterized in that: The preparation method of the emulsified bovine spleen peptide lysine powder includes: Bovine spleen peptide lysine powder, phospholipids, and sucrose esters are dissolved in pure water at 40-45℃ in a mass ratio of 10:(0.8-1.2):(0.3-0.5). The homogenization pressure is 35-40MPa, and the spray drying inlet air temperature is ≤130℃.

3. The milk powder according to claim 1, characterized in that: The pH adjuster is encapsulated in the maltodextrin carrier in microcapsule form before dry mixing, with an encapsulation rate of ≥95%.

4. The milk powder according to claim 1, characterized in that: The probiotic complex contains Bifidobacterium lactis subsp. Bb-12 and Bifidobacterium lactis subsp. HN019 in a 1:1 ratio and is pre-coated with sodium L-ascorbate.

5. The milk powder according to claim 1, characterized in that: The mass ratio of the emulsified bovine spleen peptide lysine powder to polydextrose is 1:(2-3).

6. A method for preparing bovine spleen peptide lysine-based infant formula milk powder, characterized in that, The bovine spleen peptide lysine infant formula milk powder according to any one of claims 1-5 comprises the following steps: S1. Preparation of wet-process base powder: Mix the wet-process components with water evenly, pasteurize and then spray dry, controlling the moisture content of the base powder to ≤4.5% and the pH to 6.6~6.8; S2, Bovine spleen peptide lysine pretreatment: Emulsified bovine spleen peptide lysine powder is premixed with pH adjuster and bone collagen peptide powder to form a homogeneous powder. S3, gradient mixing; Gradient mixing specifically includes the following steps: S301. Mix the powder obtained in step 2 with docosahexaenoic acid and arachidonic acid at low speed under nitrogen protection, 10-15 rpm, for 5 min. S302, add probiotic complex, 2'-fucosylated lactose and natural extract and mix at 20-25℃ for 8 minutes; S303. Transfer the wet-process base powder into a two-dimensional shear mixer and mix it with the aforementioned mixture at 12-15°C in an inert gas environment for 15 minutes. S304, sieved, nitrogen-filled packaging, oxygen residue ≤0.5%.

7. The preparation process of CBP lysine-based infant growth milk powder according to claim 6, characterized in that, Includes the following steps: In step two, during the pretreatment of bovine spleen peptide lysine, 20%–30% of the total amount of polydextrose is added as a dispersion carrier, and the mixing temperature is ≤30℃.

8. The preparation process of CBP lysine-based infant growth milk powder according to claim 6, characterized in that, The process includes the following steps: Segmented temperature control mixing is used in S303. The cavity temperature is 12-15℃ for the first 5 minutes and then drops to 8-10℃ for the next 10 minutes.

9. The preparation process of CBP lysine-based infant growth milk powder according to claim 6, characterized in that, Includes the following steps: The gradient mixing process is monitored online, and pH adjustment microcapsules are automatically sprayed when the system pH deviates from 6.6 to 6.

7.

10. The preparation process of CBP lysine-based infant growth milk powder according to claim 6, characterized in that, Includes the following steps: The final milk powder reconstitution sedimentation rate is ≤3.5%, the bovine spleen peptide lysine solubility rate is ≥98%, and the pH stability change value after 6 months of storage at 25℃ is ≤0.2.

Images